by Truveta staff | Jul 30, 2024 | Data
By the time most women with ovarian cancer are diagnosed, 70-80% are already at an advanced stage of the disease. Despite declining mortality rates over the past decade, the 5-year survival rate for patients with ovarian cancer remains less than 30%. Sometimes...
by Truveta staff | Jun 14, 2024 | Data
One in every four US households has someone living with migraine. More than a severe headache, migraine is a complex neurological disorder impacting 39 million Americans with more than $36B lost each year in medical expenses and lost productivity. Despite its...
by Truveta staff | May 20, 2024 | Data
You probably know someone who will be diagnosed with prostate cancer in their lifetime. 1 in 8 men will develop prostate cancer, with a higher risk in Black and African American men and an overall increased risk after the age of 65. While most cases are not fatal,...
by Truveta staff | Apr 18, 2024 | Data
In 2019, the US government unveiled the ambitious Ending the HIV Epidemic (EHE) plan, aiming to slash new HIV infections by 90% by 2030. Thanks to advances in antiretroviral therapy (ART), proven models of prevention, and data access, new HIV infections declined 12%...
by Truveta staff | Apr 4, 2024 | Data
US spending on medical devices and in-vitro diagnostics totals more than $199 billion a year, with most of the costs associated with clinical development. Label expansion provides a pathway for recouping costs associated with the device development process by...
by Truveta staff | Apr 2, 2024 | Data
A common misconception is that drugs and devices must gain explicit approval from the FDA for each specific use before healthcare providers can employ them. However, a practice known as off-label use challenges this notion, revealing a broader landscape of treatment...
